A randomized, double-blind, double-dummy, parallel group, international multi center study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporary combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer

Trial Profile

A randomized, double-blind, double-dummy, parallel group, international multi center study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporary combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Netupitant/palonosetron (Primary) ; Aprepitant; Dexamethasone; Granisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Sponsors Helsinn
  • Most Recent Events

    • 28 Oct 2017 Results published in the Annals of Oncology Journal.
    • 18 Oct 2017 Results of a post-hoc analysis assessing the efficacy of the Netupitant/palonosetron versus Aprepitant/Granisetron within the lung cancer subset of patients (n=542), presented at the 18th World Conference on Lung Cancer.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top